Cas:52415-29-9 6-bromoindole manufacturer & supplier

We serve Chemical Name:6-bromoindole CAS:52415-29-9 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.

6-bromoindole

Chemical Name:6-bromoindole
CAS.NO:52415-29-9
Synonyms:6-brom-1H-indole;6-BROMINDOL;6-Bromoindole;bromoindole-6;1H-Indole, 6-bromo-;6-Bromo-1H-indole;6-bromo-1 H-indole;MFCD00238550
Molecular Formula:C8H6BrN
Molecular Weight:196.044
HS Code:2942000000

Physical and Chemical Properties:
Melting point:92-96 °C(lit.)
Boiling point:316.9±15.0 °C at 760 mmHg
Density:1.7±0.1 g/cm3
Index of Refraction:1.712
PSA:15.79000
Exact Mass:194.968353
LogP:2.91

Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:NONH for all modes of transpor
Packing Group:


Contact us for information like 6-brom-1H-indole chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,MFCD00238550 physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,bromoindole-6 Use and application,6-Bromo-1H-indole technical grade,usp/ep/jp grade.


Related News: Rigosertib, Onconova��s lead candidate, is a proprietary Phase 3 small molecule. 6-bromoindole manufacturer Rigosertib, Onconova��s lead candidate, is a proprietary Phase 3 small molecule. 6-bromoindole supplier We have leading expertise in strategy and operational implementation of pre-approval access programs making pharmaceutical products under clinical development available for patients and Inceptua��s clinical trial services business offers high quality clinical comparator sourcing and manufacturing services with an agile global supply chain to ensure that products are delivered exactly when needed. 6-bromoindole vendor The API can be directly formulated, and the intermediate can only be used to synthesize the next product. Only through the intermediate can the API be manufactured. 6-bromoindole factory Rigosertib, Onconova��s lead candidate, is a proprietary Phase 3 small molecule.